BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has been given an average rating of “Moderate Buy” by the five research firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $15.60.

A number of equities research analysts have issued reports on the stock. Needham & Company LLC reiterated a “buy” rating and set a $14.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Royal Bank of Canada reiterated an “outperform” rating and set a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Finally, Barclays increased their price objective on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 5th.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

A number of hedge funds have recently made changes to their positions in BCRX. Price T Rowe Associates Inc. MD boosted its stake in shares of BioCryst Pharmaceuticals by 15.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 130,775 shares of the biotechnology company’s stock valued at $665,000 after purchasing an additional 17,091 shares in the last quarter. Tidal Investments LLC acquired a new stake in BioCryst Pharmaceuticals during the 1st quarter worth approximately $282,000. CWM LLC boosted its position in BioCryst Pharmaceuticals by 200.0% during the 2nd quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock worth $35,000 after buying an additional 3,772 shares during the period. Diversified Trust Co boosted its position in BioCryst Pharmaceuticals by 18.0% during the 2nd quarter. Diversified Trust Co now owns 24,752 shares of the biotechnology company’s stock worth $153,000 after buying an additional 3,774 shares during the period. Finally, Bank of New York Mellon Corp boosted its position in BioCryst Pharmaceuticals by 12.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 775,957 shares of the biotechnology company’s stock worth $4,795,000 after buying an additional 86,249 shares during the period. 85.88% of the stock is currently owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Stock Performance

NASDAQ:BCRX opened at $7.93 on Wednesday. BioCryst Pharmaceuticals has a 52 week low of $4.03 and a 52 week high of $8.88. The firm has a market cap of $1.64 billion, a price-to-earnings ratio of -13.00 and a beta of 1.79. The firm’s 50-day simple moving average is $7.60 and its 200 day simple moving average is $7.37.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, hitting analysts’ consensus estimates of ($0.07). The business had revenue of $117.10 million for the quarter, compared to the consensus estimate of $113.99 million. During the same period in the prior year, the business posted ($0.19) earnings per share. BioCryst Pharmaceuticals’s revenue was up 35.1% compared to the same quarter last year. Sell-side analysts anticipate that BioCryst Pharmaceuticals will post -0.38 EPS for the current year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.